BIC 2024 — 6th Asia Biologics Innovation Conference Now Open for Registration!

In recent years, benefiting from pharmaceutical regulatory reforms, Chinese biopharmaceutical companies have continuously strengthened their innovation capabilities and achieved a steady stream of innovative outcomes. Milestones include the market launch of the first domestically developed antibody-drug conjugate (ADC), the first chimeric antigen receptor T-cell (CAR-T) therapy approved for marketing in China, the first domestic bispecific antibody innovator drug, and the initial overseas regulatory submission of a domestically originated PD-1 inhibitor. These achievements demonstrate the determination of Chinese enterprises to embark on an innovation-driven transformation and indicate that initial results are being realized.

BIC 2024—The 6th Asian Biopharmaceutical Innovation Summit will focus on topics such as novel ADC/XDC platforms, bioanalysis and quality control of ADCs, bispecific/multispecific antibodies, fusion proteins/nanobodies, continuous bioprocessing for biologics, innovative upstream and downstream process development, quality control testing of biologics, quality control strategies for CGT products, CMC strategies, novel vaccine development, cell line development, and single-use technologies.

Scan the QR Code to Register for the Conference